The GlycoMark test is an FDA-cleared, non-fasting serum or plasma test for monitoring blood glucose variability in people with diabetes. The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.
The GlycoMark 1,5-anhydroglucitol biomarker was discovered to be linked to diabetes by a Japanese researcher in the 1980s. Over 1,300 studies and abstracts have been detailed in publications and in the scientific community relative to 1,5-AG worldwide.
GlycoMark, Inc. is a joint venture of Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan). GlycoMark, Inc. brings exceptional resources to the discovery and commercialization of innovative biomarkers for diabetes.
Nippon Kayaku, Co., Ltd., a major Japanese pharmaceutical and biochemical firm, makes the GlycoMark test. Toyota Tsusho Corporation imports the GlycoMark test from Japan and provides commercialization support through GlycoMark, Inc.
Hirotaka `Hiro` Ishibashi
Hiro has more than ten years of experience in the biotech industry, specifically with diabetes and its related complications. He has worked in research and analysis of regulatory and industry developments in the U.S. pharmaceutical and biotech market. Hiro has extensive global business development experience in Europe, Asia, the Middle East and Latin America. Hiro holds a Master’s degree in Biotechnology from Columbia University.
Jeff Dahlen, Ph.D.
Vice President of Clinical and Scientific Affairs
Jeff Dahlen, Ph.D., has worked in the in-vitro diagnostics industry for more than 15 years. Prior to joining GlycoMark, he held leadership positions in assay development, clinical affairs, regulatory affairs, medical affairs, and scientific affairs at Biosite, Oculir, and Accumetrics.
Jeff holds a Bachelor of Science degree in Engineering from the University of Illinois and a Ph.D. in Biomedical Sciences (Biochemistry and Molecular Biology) from the University of New Mexico.
Marketing and Partner Relations
Lauren brings extensive commercial and clinical diagnostics experience to GlycoMark, with over 20 years of sales, distribution and marketing management experience with Roche Diagnostics, Biosite, Accumetrics and is co-Founder of L3 Healthcare. Lauren focuses on clinical market education and awareness of the GlycoMark Test to help advance the care of patients with diabetes to a broader market segment. She holds a Bachelor’s degree in international business from the University of South Florida.
Kirsten possesses over ten years of management and marketing experience. She has worked with L3 since 2013 and provides world-class support and project management spanning graphic design, tradeshow management, event planning and the development of marketing, corporate and investor materials. Kirsten is currently in a Bachelor’s transfer program at San Diego City College.